AIM: To determine whether cellular apoptosis is a suitable phenotypic trait for pharmacogenomics studies by evaluating caspase 3/7-mediated activity in lymphoblastoid cell lines after treatment with six chemotherapeutic agents: 5'-deoxyfluorouridine, pemetrexed, cytarabine, paclitaxel, carboplatin, and cisplatin. MATERIALS AND METHODS: Using monozygotic twin pair and sibling pair lymphoblastoid cell lines, we identified conditions for measurement of caspase 3/7 activity in lymphoblastoid cell lines. Genome-wide association studies were performed with over 2 million single nucleotide polymorphisms (SNPs) and cisplatin-induced apoptosis in HapMap CEU cell lines (n=77). RESULTS: Although treatment with 5'-deoxyfluorouridine and pemetrexed for up to 24 h resulted in low levels of apoptosis or interindividual variation in caspase-dependent cell death; paclitaxel, cisplatin, carboplatin, and cytarabine treatment for 24 h resulted in 9.4-fold, 9.1-fold, 7.0-fold, and 6.0-fold increases in apoptosis relative to control, respectively. There was a weak correlation between caspase activity and cytotoxicity (r(2)=0.03-0.29) demonstrating that cytotoxicity and apoptosis are two distinct phenotypes that may produce independent genetic associations. Estimated heritability (h(2)) for apoptosis was 0.57 and 0.29 for cytarabine (5 and 40 μmol/l, respectively), 0.22 for paclitaxel (12.5 nmol/l), and 0.34 for cisplatin (5 μmol/l). In the genome-wide association study using the HapMap CEU panel, we identified a significant enrichment of cisplatin-induced cytotoxicity SNPs within the significant cisplatin-induced apoptosis SNPs and an enrichment of expression quantitative trait loci (eQTL). Among these eQTLs, we identified several eQTLs with known function related to apoptosis and/or cytotoxicity. CONCLUSION: Our study identifies apoptosis as a phenotype for pharmacogenomic studies in lymphoblastoid cell lines after treatment with paclitaxel, cisplatin, carboplatin, and cytarabine that may have utility for discovering biomarkers to predict response to certain chemotherapeutics.
AIM: To determine whether cellular apoptosis is a suitable phenotypic trait for pharmacogenomics studies by evaluating caspase 3/7-mediated activity in lymphoblastoid cell lines after treatment with six chemotherapeutic agents: 5'-deoxyfluorouridine, pemetrexed, cytarabine, paclitaxel, carboplatin, and cisplatin. MATERIALS AND METHODS: Using monozygotic twin pair and sibling pair lymphoblastoid cell lines, we identified conditions for measurement of caspase 3/7 activity in lymphoblastoid cell lines. Genome-wide association studies were performed with over 2 million single nucleotide polymorphisms (SNPs) and cisplatin-induced apoptosis in HapMap CEU cell lines (n=77). RESULTS: Although treatment with 5'-deoxyfluorouridine and pemetrexed for up to 24 h resulted in low levels of apoptosis or interindividual variation in caspase-dependent cell death; paclitaxel, cisplatin, carboplatin, and cytarabine treatment for 24 h resulted in 9.4-fold, 9.1-fold, 7.0-fold, and 6.0-fold increases in apoptosis relative to control, respectively. There was a weak correlation between caspase activity and cytotoxicity (r(2)=0.03-0.29) demonstrating that cytotoxicity and apoptosis are two distinct phenotypes that may produce independent genetic associations. Estimated heritability (h(2)) for apoptosis was 0.57 and 0.29 for cytarabine (5 and 40 μmol/l, respectively), 0.22 for paclitaxel (12.5 nmol/l), and 0.34 for cisplatin (5 μmol/l). In the genome-wide association study using the HapMap CEU panel, we identified a significant enrichment of cisplatin-induced cytotoxicity SNPs within the significant cisplatin-induced apoptosis SNPs and an enrichment of expression quantitative trait loci (eQTL). Among these eQTLs, we identified several eQTLs with known function related to apoptosis and/or cytotoxicity. CONCLUSION: Our study identifies apoptosis as a phenotype for pharmacogenomic studies in lymphoblastoid cell lines after treatment with paclitaxel, cisplatin, carboplatin, and cytarabine that may have utility for discovering biomarkers to predict response to certain chemotherapeutics.
Authors: Devangi S Mehta; Andrea L Wurster; Matthew J Whitters; Deborah A Young; Mary Collins; Michael J Grusby Journal: J Immunol Date: 2003-04-15 Impact factor: 5.422
Authors: S-H Chen; W Yang; Y Fan; G Stocco; K R Crews; J J Yang; S W Paugh; C-H Pui; W E Evans; M V Relling Journal: Leukemia Date: 2010-11-12 Impact factor: 11.528
Authors: Karen S Ballard; Howard D Homesley; Charles Hodson; Cary A Presant; James Rutledge; Allan Hallquist; Mathieu Perree Journal: J Gynecol Oncol Date: 2010-03-31 Impact factor: 4.401
Authors: Maryann B Flick; David O'Malley; Thomas Rutherford; Sofya Rodov; Marijka Kamsteeg; Xiao-Ying Hao; Peter Schwartz; Barry M Kacinski; Gil Mor Journal: J Soc Gynecol Investig Date: 2004-05
Authors: Uchenna O Njiaju; Eric R Gamazon; Lidija K Gorsic; Shannon M Delaney; Heather E Wheeler; Hae Kyung Im; M Eileen Dolan Journal: Pharmacogenet Genomics Date: 2012-07 Impact factor: 2.089
Authors: Luis J Leandro-García; Susanna Leskelä; Carlos Jara; Henrik Gréen; Elisabeth Avall-Lundqvist; Heather E Wheeler; M Eileen Dolan; Lucia Inglada-Perez; Agnieszka Maliszewska; Aguirre A de Cubas; Iñaki Comino-Méndez; Veronika Mancikova; Alberto Cascón; Mercedes Robledo; Cristina Rodríguez-Antona Journal: Clin Cancer Res Date: 2012-06-20 Impact factor: 12.531
Authors: Dana Ziliak; Eric R Gamazon; Bonnie Lacroix; Hae Kyung Im; Yujia Wen; Rong Stephanie Huang Journal: Mol Cancer Ther Date: 2012-06-29 Impact factor: 6.261
Authors: Eric R Gamazon; Jatinder K Lamba; Stanley Pounds; Amy L Stark; Heather E Wheeler; Xueyuan Cao; Hae K Im; Amit K Mitra; Jeffrey E Rubnitz; Raul C Ribeiro; Susana Raimondi; Dario Campana; Kristine R Crews; Shan S Wong; Marleen Welsh; Imge Hulur; Lidija Gorsic; Christine M Hartford; Wei Zhang; Nancy J Cox; M Eileen Dolan Journal: Blood Date: 2013-03-28 Impact factor: 22.113
Authors: Hae Kyung Im; Eric R Gamazon; Amy L Stark; R Stephanie Huang; Nancy J Cox; M Eileen Dolan Journal: PLoS Genet Date: 2012-02-09 Impact factor: 5.917